硫普羅寧聯(lián)合恩替卡韋治療慢性乙型肝炎的臨床效果

打開文本圖片集

Clinical Effect of Tiopronin Combined with Entecavir in the Treatment of Chronic Hepatitis B/ ZHANG Heng， ZHU Zhengxin， ZHU Zhengwei. /Medical Innovation of China， 2025， 22（11）： 038-042

[Abstract]Objective： To explore the clinical effct of Tiopronin combined with Entecavir in the treatment ofchronic hepatitis B.Method：Atotalof 80patients withchronichepatitis Badmitted to Shangrao Second People's Hospital from May 2022 to April 2024 were selected and divided into two groups according to random number method， with 40 cases ineach group.The control group was given Entecavir，and the observation group was given Tioproninon thebasis of controlgroup.Theclinicaleffcacy，liver function，liver fibrosis indexes，inflammatory factors and adverse reactions were compared between the two groups. Result： The total efective rate of the observation group was higher than that of the control group，the difference was statistically significant （ P <0.05）.After treatment， the liverfunction，liverfibrosis and inflammatoryfactors indexes levels inthe observation group were lower than those in the control group， the differences were statistically significant （P<0.05 . There was no significant difference in the incidence of adverse reactions between the two groups （P>0.05 . Conclusion： Tiopronin combined withEntecavir inthetreatmentofchronichepatitisBhasdefinite clinicalefect，can improve patients'liverfunction and reduce inflammatory reaction， and has good safety.

[Key words] Tiopronin Entecavir Chronic hepatitis B Liver fibrosis Liver function Adverse reactions

First-author's address： Department of Gastroenterology， Shangrao Second People's Hospital hangrao 334000， China

doi：10.3969/j.issn.1674-4985.2025.11.009

慢性乙型肝炎是由母嬰傳播、性接觸、血液傳播、破損皮膚黏膜等途徑感染乙型肝炎病毒所致-2]。（剩余6113字）